{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:58:58Z","timestamp":1790827138981,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA033572"],"award-info":[{"award-number":["P30 CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:49:18Z","timestamp":1751572158000},"page":"824.e1-824.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment"],"prefix":"10.1016","volume":"31","author":[{"given":"Tina","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Markary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Tiemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-4612","authenticated-orcid":false,"given":"Hoda","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Blackmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukaib","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-8805","authenticated-orcid":false,"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoroenyi","family":"Amanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-7023","authenticated-orcid":false,"given":"Brian","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-8484","authenticated-orcid":false,"given":"Karamjeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2025.07.001_bib0001","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2004-03-0804","article-title":"Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors","volume":"104","author":"Diaconesco","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.001_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.1993.03510010063030","article-title":"Outcome after allogeneic bone marrow transplant for leukemia in older adults","volume":"270","author":"Ringden","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.001_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/bmt.2014.199","article-title":"Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML","volume":"50","author":"Sebert","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.07.001_bib0004","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.07.001_bib0005","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.001_bib0006","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","article-title":"Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes","volume":"100","author":"Martino","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbmt.2009.05.006","article-title":"Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation","volume":"15","author":"De Souza","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0008","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.07.001_bib0009","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2018.04.029","article-title":"Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"24","author":"Al Malki","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jtct.2025.07.001_bib0010","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.001_bib0011","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/10428194.2020.1731498","article-title":"Reduced-intensity fludarabine\/melphalan confers similar survival to busulfan\/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia","volume":"61","author":"DiMaggio","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.07.001_bib0012","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.1182\/blood-2022-167757","article-title":"Outcome of patients undergoing hematopoietic cell transplantation for TP53-mutated acute leukemias and MDS: effect of conditioning and GVHD prophylaxis regimens intensity [abstract]","volume":"140","author":"Desai","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.001_bib0013","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.001_bib0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jtct.2021.02.030","article-title":"Impact of pre-transplant renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation","volume":"27","author":"Farhadfar","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.001_bib0016","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.bbmt.2018.05.005","article-title":"Baseline renal function and albumin are powerful predictors for allogeneic transplantation-related mortality","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.07.001_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-012-1584-1","article-title":"Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation","volume":"92","author":"Oshima","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.001_bib0018","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.semnephrol.2010.09.008","article-title":"Hematopoietic stem cell transplantation in patients with chronic kidney disease","volume":"30","author":"Heher","year":"2010","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.001_bib0019","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","article-title":"Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens","volume":"61","author":"Shah","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.001_bib0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/10428194.2011.604756","article-title":"Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity","volume":"53","author":"Van Besien","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/1078155220927436","article-title":"Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan","volume":"27","author":"Sweiss","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.001_bib0022","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2014.02.013","article-title":"Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations","volume":"20","author":"Bodge","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.001_bib0023","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3109\/10428194.2012.762978","article-title":"Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future","volume":"54","author":"Ram","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.001_bib0024","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/bmt.2016.136","article-title":"Melphalan 200\u2009mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival","volume":"51","author":"Sweiss","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.001_bib0025","first-page":"947","article-title":"Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study","volume":"2","author":"Tricot","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.001_bib0026","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1054\/bjoc.2001.1928","article-title":"Glomerular filtration rate prior to high-dose melphalan 200 mg\/m(2) as a surrogate marker of outcome in patients with myeloma","volume":"85","author":"Sirohi","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.001_bib0028","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0029","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41409-020-01010-1","article-title":"Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Bone Marrow","volume":"56","author":"Beksac","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.07.001_bib0030","unstructured":"Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.https:\/\/kdigo.org\/guidelines\/ckd-evaluation-and-management\/. Accessed October 1, 2023."},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0031","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbmt.2015.10.015","article-title":"Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning","volume":"22","author":"Brammer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.001_bib0032","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma","volume":"25","author":"Saini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.001_bib0033","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbmt.2013.07.008","article-title":"A randomized phase II trial of fludarabine\/melphalan 100 versus fludarabine\/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma","volume":"19","author":"Bashir","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.001_bib0034","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.bbmt.2020.04.015","article-title":"Long-term outcomes of allogeneic hematopoietic cell transplant with fludarabine and melphalan conditioning and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis in patients with acute lymphoblastic leukemia","volume":"26","author":"Mei","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2025.07.001_bib0035","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.001_bib0036","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.001_bib0037","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.07.001_bib0038","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2025.07.001_bib0039","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"18","key":"10.1016\/j.jtct.2025.07.001_bib0041","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood.2021011867","article-title":"Graft-versus-host disease: a disorder of tissue regeneration and repair","volume":"138","author":"Chakraverty","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.07.001_bib0042","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-021-04273-7","article-title":"Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever","volume":"88","author":"Wardill","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.001_bib0043","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.06870909","article-title":"Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size","volume":"5","author":"Michels","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.001_bib0044","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","article-title":"Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations","volume":"54","author":"Stevens","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:38:32Z","timestamp":1790825912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725012874"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}